Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
Late-stage data are expected for Apellis; Ionis and Biogen tackle ALS; and Mirati awaits combination results.
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
Altimmune’s early-stage obesity hit is impressive, but big pharma has more advanced rivals.